Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Cortes

Showing results (1-10 of 231) with videos related to

Pageof 24
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 9, 2011
Nontaxane microtubule dynamics inhibitorsJavier Cortes
Cancer Chemotherapy and Biological Response Modifiers|August 23, 2005
Epidermal growth factor receptor pathway inhibitorsJose Baselga, Javier Cortes
Cancer Treatment Reviews|August 30, 2011
Docetaxel combined with targeted therapies in metastatic breast cancerJavier Cortes, Henri Roché
Breast Cancer Research and Treatment|November 25, 2011
Beyond taxanes: the next generation of microtubule-targeting agentsJavier Cortes, Maria Vidal
Future Oncology (London, England)|March 8, 2011
Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancerJavier Cortes, Rebeca Lorca
The Oncologist|April 5, 2007
Targeting the microtubules in breast cancer beyond taxanes: the epothilonesJavier Cortes, Jose Baselga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancerJavier Cortes, José Baselga
The Breast Journal|November 30, 2019
Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysisJavier Cortes, Chris Twelves
Nature Reviews. Clinical Oncology|December 13, 2017
Breast cancer in 2017: Spurring science, marking progress, and influencing historyJose Perez-Garcia, Javier Cortes
European Journal of Cancer (Oxford, England : 1990)|April 23, 2018
The new world of biosimilars in oncology: Translation of data to the clinicHope S Rugo, Javier Cortes
Pageof 24

Showing results (1-10 of 231) with videos related to

Sort By:
Pageof 24
Clinical Advances in Hematology & Oncology : H&O|April 9, 2011
Nontaxane microtubule dynamics inhibitorsJavier Cortes
Cancer Chemotherapy and Biological Response Modifiers|August 23, 2005
Epidermal growth factor receptor pathway inhibitorsJose Baselga, Javier Cortes
Cancer Treatment Reviews|August 30, 2011
Docetaxel combined with targeted therapies in metastatic breast cancerJavier Cortes, Henri Roché
Breast Cancer Research and Treatment|November 25, 2011
Beyond taxanes: the next generation of microtubule-targeting agentsJavier Cortes, Maria Vidal
Future Oncology (London, England)|March 8, 2011
Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancerJavier Cortes, Rebeca Lorca
The Oncologist|April 5, 2007
Targeting the microtubules in breast cancer beyond taxanes: the epothilonesJavier Cortes, Jose Baselga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancerJavier Cortes, José Baselga
The Breast Journal|November 30, 2019
Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysisJavier Cortes, Chris Twelves
Nature Reviews. Clinical Oncology|December 13, 2017
Breast cancer in 2017: Spurring science, marking progress, and influencing historyJose Perez-Garcia, Javier Cortes
European Journal of Cancer (Oxford, England : 1990)|April 23, 2018
The new world of biosimilars in oncology: Translation of data to the clinicHope S Rugo, Javier Cortes
Pageof 24